No Data
BOCOM INTL: Maintains Buy rating for Hutchmed (China) (00013) with the Target Price raised to 44 HKD.
BOCOM INTL believes that the conditions of this Trade involving Hutchmed (China) are reasonable and beneficial for the company's long-term development.
[Brokerage Focus] BOCOM INTL raised the Target Price for Hutchmed (China) (00013) by 8.9%, stating that the sale of affiliated company equity is beneficial for the company's long-term development.
Jinwu Financial News | BOCOM INTL issued a Research Report stating that Hutchmed (China) (00013) announced the sale of its 45% stake in Shanghai Hutchmed to Shanghai Jinpu Health and SH PHARMA for $0.608 billion (approximately 14 times the 2023 PE) in Cash. Jinpu Health and SH PHARMA will acquire 35% and 10% stakes in Shanghai Hutchmed for $0.473 billion and $135 million in Cash, respectively, while Hutchmed will retain a 5% stake after the Trade. The company expects the above transaction to yield $0.477 billion in pre-tax profit, most of which will be reflected in the 2025 results. The firm indicated that the company plans to use the proceeds from the above.
BofA Securities Cuts Price Target on HUTCHMED to $26 From $30, Maintains Buy Rating
BofA Securities Maintains Hutchmed (China)(HCM.US) With Buy Rating, Cuts Target Price to $26
Pharmaceutical stocks have become a transitional theme at present, and the performance line may be further valued by the market.
Track the entire lifecycle of the main sector.
Hong Kong stock movement | Hutchmed (China) (00013) rises over 4%. The company's sale of non-core Traditional Chinese Medicine Assets will further strengthen its capital and debt structure.
Hutchmed (China) (00013) rose over 4%, as of the time of writing, it increased by 4.3%, trading at HKD 24.25, with a transaction volume of HKD 61.2538 million.
No Data
